AU2012327205B2 - Genetically modified major histocompatibility complex mice - Google Patents

Genetically modified major histocompatibility complex mice Download PDF

Info

Publication number
AU2012327205B2
AU2012327205B2 AU2012327205A AU2012327205A AU2012327205B2 AU 2012327205 B2 AU2012327205 B2 AU 2012327205B2 AU 2012327205 A AU2012327205 A AU 2012327205A AU 2012327205 A AU2012327205 A AU 2012327205A AU 2012327205 B2 AU2012327205 B2 AU 2012327205B2
Authority
AU
Australia
Prior art keywords
human
mhc
mouse
chimeric
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012327205A
Other languages
English (en)
Other versions
AU2012327205A1 (en
Inventor
Cagan Gurer
Lynn Macdonald
Andrew J. Murphy
Sean Stevens
Naxin Tu
Vera VORONINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2012327205A1 publication Critical patent/AU2012327205A1/en
Application granted granted Critical
Publication of AU2012327205B2 publication Critical patent/AU2012327205B2/en
Priority to AU2016202317A priority Critical patent/AU2016202317B2/en
Priority to AU2018201402A priority patent/AU2018201402C1/en
Priority to AU2021200438A priority patent/AU2021200438B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2012327205A 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice Active AU2012327205B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2016202317A AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice
AU2018201402A AU2018201402C1 (en) 2011-10-28 2018-02-27 Genetically Modified Major Histocompatibility Complex Mice
AU2021200438A AU2021200438B2 (en) 2011-10-28 2021-01-22 Genetically Modified Major Histocompatibility Complex Mice

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552584P 2011-10-28 2011-10-28
US61/552,584 2011-10-28
PCT/US2012/062029 WO2013063340A1 (en) 2011-10-28 2012-10-26 Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202317A Division AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice

Publications (2)

Publication Number Publication Date
AU2012327205A1 AU2012327205A1 (en) 2013-05-23
AU2012327205B2 true AU2012327205B2 (en) 2016-01-14

Family

ID=47430036

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2012327205A Active AU2012327205B2 (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice
AU2016202317A Active AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice
AU2018201402A Active AU2018201402C1 (en) 2011-10-28 2018-02-27 Genetically Modified Major Histocompatibility Complex Mice
AU2021200438A Active AU2021200438B2 (en) 2011-10-28 2021-01-22 Genetically Modified Major Histocompatibility Complex Mice

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2016202317A Active AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice
AU2018201402A Active AU2018201402C1 (en) 2011-10-28 2018-02-27 Genetically Modified Major Histocompatibility Complex Mice
AU2021200438A Active AU2021200438B2 (en) 2011-10-28 2021-01-22 Genetically Modified Major Histocompatibility Complex Mice

Country Status (25)

Country Link
US (7) US8847005B2 (cg-RX-API-DMAC7.html)
EP (4) EP4052572B8 (cg-RX-API-DMAC7.html)
JP (2) JP6285361B2 (cg-RX-API-DMAC7.html)
KR (2) KR101926442B1 (cg-RX-API-DMAC7.html)
CN (3) CN108401986B (cg-RX-API-DMAC7.html)
AU (4) AU2012327205B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014009941B1 (cg-RX-API-DMAC7.html)
CA (1) CA2852962C (cg-RX-API-DMAC7.html)
CY (3) CY1119283T1 (cg-RX-API-DMAC7.html)
DK (3) DK3590332T3 (cg-RX-API-DMAC7.html)
ES (3) ES2914374T3 (cg-RX-API-DMAC7.html)
HR (3) HRP20220616T1 (cg-RX-API-DMAC7.html)
HU (2) HUE048511T2 (cg-RX-API-DMAC7.html)
IL (3) IL231895B (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03892A (cg-RX-API-DMAC7.html)
LT (3) LT3590332T (cg-RX-API-DMAC7.html)
MX (2) MX355726B (cg-RX-API-DMAC7.html)
PL (3) PL3590332T3 (cg-RX-API-DMAC7.html)
PT (3) PT3590332T (cg-RX-API-DMAC7.html)
RS (3) RS59997B1 (cg-RX-API-DMAC7.html)
RU (1) RU2660564C2 (cg-RX-API-DMAC7.html)
SG (3) SG10201909638UA (cg-RX-API-DMAC7.html)
SI (3) SI3272214T1 (cg-RX-API-DMAC7.html)
SM (3) SMT201700437T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013063340A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065730A3 (en) 2006-04-26 2012-09-19 L-3 Communications Security and Detection Systems, Inc. Multi-source surveillance systems
WO2013063556A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
LT3590332T (lt) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SMT201900429T1 (it) 2013-02-20 2019-09-09 Regeneron Pharma Topi esprimenti co-recettori umanizzati linfociti t
EP2958937B1 (en) * 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
JP6456350B2 (ja) * 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
DK4269430T3 (da) 2013-09-23 2025-08-18 Regeneron Pharma Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen
SI3138397T1 (sl) * 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
NO2785538T3 (cg-RX-API-DMAC7.html) 2014-05-07 2018-08-04
WO2015196051A1 (en) * 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
RS63410B1 (sr) 2014-11-24 2022-08-31 Regeneron Pharma Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
BR112017010490A2 (pt) 2014-12-05 2018-04-03 Regeneron Pharma roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
LT3230320T (lt) 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
DK3280257T3 (da) 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
LT3376857T (lt) 2015-11-20 2021-06-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
CA3012693C (en) * 2016-02-04 2022-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
EP3462853B1 (en) 2016-06-03 2023-03-01 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
AU2018375796B2 (en) 2017-11-30 2024-11-21 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
HUE070158T2 (hu) 2018-03-24 2025-05-28 Regeneron Pharma Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
AU2019242586B2 (en) 2018-03-26 2025-09-11 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
PL3823443T3 (pl) 2018-07-16 2024-09-23 Regeneron Pharmaceuticals, Inc. Modele gryzoni z chorobą ditra i ich zastosowania
JP7685249B2 (ja) * 2019-10-22 2025-05-29 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク トランスジェニックブタ、その作製方法と用途、およびヒト免疫系マウスの作製方法
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
KR20250077529A (ko) 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
AU633958B2 (en) 1989-07-25 1993-02-11 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
US6147275A (en) * 1998-03-30 2000-11-14 Research Development Foundation Corticotropin releasing factor receptor 1-deficient mice
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7067308B1 (en) * 2000-03-28 2006-06-27 Bioagri Corporation Vector for genetically modifying non-human animals
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
US20030093818A1 (en) 2000-12-19 2003-05-15 Belmont Heather J. Transgenic animals comprising a humanized immune system
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
JP4857450B2 (ja) 2004-03-09 2012-01-18 財団法人名古屋産業科学研究所 ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
EP1878342A1 (en) * 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
EP2517556B2 (en) 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
CN101695587B (zh) * 2009-10-21 2012-08-29 上海中山医疗科技发展公司 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法
CA2805479A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
LT3590332T (lt) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
SMT201900429T1 (it) 2013-02-20 2019-09-09 Regeneron Pharma Topi esprimenti co-recettori umanizzati linfociti t
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
JP6456350B2 (ja) 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
DK3280257T3 (da) 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ITO, K., et al., Journal of Experimental Medicine, 1996, vol. 183, pages 2635-2644 *
WOODS, A., et al., Journal of Experimental Medicine, 1994, vol. 180, pages 173-181 *

Also Published As

Publication number Publication date
BR112014009941A2 (pt) 2020-12-22
CY1125196T1 (el) 2025-03-28
CA2852962C (en) 2022-05-03
KR20140089558A (ko) 2014-07-15
SG10201510056SA (en) 2016-01-28
EP2770822B1 (en) 2017-06-14
CN108707608A (zh) 2018-10-26
HK1250131A1 (en) 2018-11-30
AU2016202317A1 (en) 2016-05-05
SG10201909638UA (en) 2019-11-28
NZ717130A (en) 2018-07-27
US11219195B2 (en) 2022-01-11
IL260209A (en) 2018-07-31
IL260209B (en) 2019-12-31
EP4052572A1 (en) 2022-09-07
EP3272214A1 (en) 2018-01-24
AU2018201402A1 (en) 2018-03-15
SG11201400938UA (en) 2014-04-28
HRP20200305T1 (hr) 2020-06-12
ES2914374T3 (es) 2022-06-10
SI2770822T1 (sl) 2017-10-30
CN104039133A (zh) 2014-09-10
KR101926442B1 (ko) 2018-12-12
HUE034374T2 (en) 2018-02-28
HUE048511T2 (hu) 2020-07-28
AU2021200438A1 (en) 2021-02-25
PT2770822T (pt) 2017-09-18
LT2770822T (lt) 2017-10-10
US20210195878A1 (en) 2021-07-01
SMT202000114T1 (it) 2020-03-13
IL231895B (en) 2018-07-31
PL3590332T3 (pl) 2022-06-13
EP3272214B1 (en) 2019-11-27
US20190239497A1 (en) 2019-08-08
AU2018201402C1 (en) 2021-05-06
JP6285361B2 (ja) 2018-02-28
DK3272214T3 (da) 2020-03-02
HRP20171327T1 (hr) 2017-11-03
CN108401986A (zh) 2018-08-17
SI3272214T1 (sl) 2020-04-30
RU2018115251A (ru) 2019-03-04
ES2640241T3 (es) 2017-11-02
US20130111616A1 (en) 2013-05-02
BR112014009941B1 (pt) 2022-11-29
CA2852962A1 (en) 2013-05-02
SMT202200205T1 (it) 2022-07-21
US20190239496A1 (en) 2019-08-08
PL3272214T3 (pl) 2020-06-29
CY1119283T1 (el) 2018-02-14
DK2770822T3 (en) 2017-09-25
RU2018115251A3 (cg-RX-API-DMAC7.html) 2021-09-07
KR20180132970A (ko) 2018-12-12
PL2770822T3 (pl) 2017-11-30
US9585373B2 (en) 2017-03-07
US8847005B2 (en) 2014-09-30
US20170135329A1 (en) 2017-05-18
EP3590332B1 (en) 2022-02-23
JP2014532411A (ja) 2014-12-08
PT3590332T (pt) 2022-05-27
RU2660564C2 (ru) 2018-07-06
LT3272214T (lt) 2020-03-10
EP3590332A1 (en) 2020-01-08
EP4052572B1 (en) 2025-11-26
LT3590332T (lt) 2022-08-10
HK1196999A1 (en) 2015-01-02
CN104039133B (zh) 2018-05-04
PT3272214T (pt) 2020-03-04
RS56330B1 (sr) 2017-12-29
WO2013063340A1 (en) 2013-05-02
AU2018201402B2 (en) 2020-10-22
AU2012327205A1 (en) 2013-05-23
RS63220B1 (sr) 2022-06-30
EP2770822B9 (en) 2019-12-11
EP2770822A1 (en) 2014-09-03
SI3590332T1 (sl) 2022-07-29
EP4052572B8 (en) 2026-01-07
MX355726B (es) 2018-04-27
AU2021200438B2 (en) 2023-11-02
US10219493B2 (en) 2019-03-05
JP2018019700A (ja) 2018-02-08
KR102113108B1 (ko) 2020-05-20
MX379060B (es) 2025-03-10
SMT201700437T1 (it) 2017-11-15
US20150040253A1 (en) 2015-02-05
IN2014CN03892A (cg-RX-API-DMAC7.html) 2015-10-16
IL243565A (en) 2017-10-31
CN108401986B (zh) 2021-09-21
ES2774488T3 (es) 2020-07-21
IL231895A0 (en) 2014-05-28
CY1122700T1 (el) 2021-03-12
US20240365761A1 (en) 2024-11-07
DK3590332T3 (da) 2022-05-23
AU2016202317B2 (en) 2017-11-30
NZ623146A (en) 2016-06-24
JP6652529B2 (ja) 2020-02-26
HRP20220616T1 (hr) 2022-06-24
US10986822B2 (en) 2021-04-27
RU2014116577A (ru) 2015-12-10
MX2014004896A (es) 2014-09-12
RS59997B1 (sr) 2020-04-30

Similar Documents

Publication Publication Date Title
AU2021200438B2 (en) Genetically Modified Major Histocompatibility Complex Mice
US20130185820A1 (en) Genetically Modified Major Histocompatibility Complex Animals
AU2014249148B2 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
HK40080877A (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK40017625B (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK40017625A (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK1250131B (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK1196999B (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
NZ717130B2 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MACDONALD, LYNN; MURPHY, ANDREW J.; TU, NAXIN; GURER, CAGAN; VORONINA, VERA AND STEVENS, SEAN

FGA Letters patent sealed or granted (standard patent)